ClinicalTrials.gg
CompletedNCT04236609ABILITYUpdated Oct 26, 2026

Randomized Comparison of Abluminus DES+ Sirolimus-Eluting Stents Versus Everolimus-Eluting Stents in Coronary Artery Disease Patients With Diabetes Mellitus Global

An interventional study of Abluminus DES+ Sirolimus Eluting Stent System (SES) and XIENCE Everolimus Eluting Coronary Stent System (XIENCE family) in Diabetes, Coronary Artery Disease and Acute Coronary Syndrome, sponsored by Concept Medical Inc.. Completed at 90 sites in 21 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Concept Medical Inc. · Not applicable, Interventional, and Other

How we know

Updated Oct 26, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
3,050
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 270 studies in Diabetes Mellitus with a site in Italy — 31 open to participants now, 42 under way, 3 of them phase 3. Diabetes Mellitus · Italy.

Enrollment
16th of 201
3,050 · median 300
Started
2020
with 10 others
No phase
64 of 270
12 open now
Registered
201st of 270
by date

Among the 270 studies in Diabetes Mellitus with a site in Italy, this one is the 16th largest by enrollment of the 201 interventional ones that give a count, is one of 11 that started in 2020, is one of 64 with no phase, and was the 201st registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

31 of the 270 studies in Diabetes Mellitus with a site in Italy are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 270 studies in Diabetes Mellitus with a site in Italy, or all of them as a file.
02

Study summary

To compare in diabetic patients eligible for percutaneous coronary intervention (PCI) with minimal exclusion criteria, the efficacy and safety of Abluminus DES+ sirolimus- eluting stents (SES) versus XIENCE Everolimus-Eluting Stents (EES). At least 40% of patients are expected to be affected by multivessel coronary artery disease and 30% with acute coronary syndrome

Read the detailed description

This study aims to determine which DES will best treat the diabetic population. Specifically, the research question of this trial is to evaluate the use of a novel sirolimus-eluting stent coated with drug-eluting polymer after crimping on the balloon as compared to the standard-of-care EES in the treatment of de novo coronary artery disease in patients with diabetes mellitus. ABILITY is a prospective, multi-center, multinational, randomized, open label, 2-arm parallel group, post-approval study.

03

Conditions studied

  • Diabetes
  • Coronary Artery Disease
  • Acute Coronary Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Clinical Inclusion Criteria

  1. Patient understands the trial requirements and the treatment procedures and provides written ;
  2. Age ≥ 18 years of age (> 19 years of age for South Korea and ≥ 21 years of age for Singapore);
  3. Diabetic patient: either:

    1. Patient with a previous documented diagnosis of diabetes mellitus (Type 1 or Type 2) and currently undergoing pharmacological treatment (oral hypoglycemic agents or insulin)
    2. Newly diagnosed diabetes: either:

    i. Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L). Fasting is defined as no caloric intake for ≥8 hours1 or ii. Two-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) following a 75g oral glucose tolerance test or iii. level ≥ 7% (53 mmol/mol) Patients who are newly diagnosed are included even if they are not on pharmacological treatment (oral hypoglycemic agents or insulin)

  4. Symptomatic coronary artery disease including chronic stable angina, silent ischemia, and non-ST-segment elevation acute coronary syndrome (NSTE-ACS)
  5. Patient is eligible for percutaneous coronary intervention (PCI); Previous PCI (with balloon angioplasty or stenting) is allowed if performed >12 months before index procedure;
  6. Patient is willing and able to comply with all protocol-required follow-up evaluations.

    Angiographic Inclusion Criteria (visual estimate)

  7. Presence of ≥1 de novo coronary artery stenosis >50% in a native coronary artery which can be treated with a stent ranging in diameter from 2.25 to 4.0 mm and can be covered with 1 or multiple stents; and
  8. No limitation to the number of treated lesions, number of vessels, or lesion length if the patient is judged eligible for PCI by the treating physician according to the local standard of care.

Exclusion criteria

Exclusion Criteria:

Clinical Exclusion Criteria

  1. Patient lacking capacity (i.e. patient suffering from dementia and others) to provide
  2. Patient in cardiogenic shock;
  3. Patient has known allergy to the study stent system or protocol-required concomitant medications (e.g. aspirin, clopidogrel, prasugrel, ticagrelor, heparin, stainless steel, platinum, chromium, sirolimus, everolimus, radiographic contrast material) that cannot be adequately pre-medicated;
  4. Planned surgery (cardiac and non-cardiac) within 6 months after the index procedure unless the dual-antiplatelet therapy (DAPT) can be maintained throughout the peri-surgical period;
  5. Patient undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI)
  6. Patient is pregnant, nursing, or is a woman of who is not surgically sterile, \< 2 years , or does not consistently use effective methods of *;
  7. Patient has any other serious medical illness (e.g., cancer, end-stage congestive heart failure) that may reduce to less than 12 months;
  8. Acute or chronic renal dysfunction (creatinine >3.0 mg/dl);
  9. Currently participating in another drug or device study.

    Angiographic Exclusion Criteria

  10. In-stent restenotic lesions;
  11. Lesions involving venous or arterial bypass grafts.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
3,050 participants (actual)

Study arms

  • Active comparator
    Abluminus DES+ sirolimus- eluting stents (SES)

    Enrolled patients will undergo angioplasty with Abluminus DES+ sirolimus- eluting stents (SES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the Abluminus DES+ sirolimus- eluting stents (SES).

    Device: Abluminus DES+ Sirolimus Eluting Stent System (SES)

  • Active comparator
    XIENCE Everolimus-Eluting Stents (EES)

    Enrolled patients will undergo angioplasty with XIENCE Everolimus-Eluting Stents (EES) and will be followed for two years. The DES procedure will be conducted in accordance with the CE mark instructions for use for the XIENCE Everolimus-Eluting Stents (EES).

    Device: XIENCE Everolimus Eluting Coronary Stent System (XIENCE family)

Interventions

  • DeviceAbluminus DES+ Sirolimus Eluting Stent System (SES)

    The Sirolimus-eluting stent manufactured by Envision and distributed by Concept Medical

  • DeviceXIENCE Everolimus Eluting Coronary Stent System (XIENCE family)

    The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA

06

What researchers measure

Primary outcomes

  1. Rate of Ischemia-driven TLR

    powered for non-inferiority and sequentially superiority

    Time frame: 1 year FU

  2. Rate of Target lesion failure TLF

    composite of cardiovascular death, target vessel myocardial infarction \[MI\], or ischemia driven target lesion revascularization \[idTLR\])

    Time frame: 1 year FU, powered for non-inferiority

Secondary outcomes

  1. Safety composite endpoint

    Safety composite endpoint of the occurrence of cardiovascular death and target-vessel myocardial infarction (MI)

    Time frame: 1 year (non-inferiority)

  2. co-primary TLR endpoint

    In case the co-primary TLR endpoint (TLR for non-inferiority) will be demonstrated at 1 year, then the occurrence of ischemia-driven TLR at 2-year FU will be evaluated (efficacy endpoint - superiority)

    Time frame: 2 Year FU

  3. Composite of cardiovascular death, target vessel MI and ischemia-driven TLR (TLF)

    Cardiovascular death is defined as death resulting from cardiovascular causes. The following categories may be collected: 1. Death caused by acute MI 2. Death caused by sudden cardiac, including unwitnessed, death 3. Death resulting from heart failure 4. Death caused by stroke 5. Death caused by cardiovascular procedures 6. Death resulting from cardiovascular hemorrhage 7. Death resulting from other cardiovascular cause Any MI not clearly attributable to a non-target vessel will be considered as target-vessel MI. * Percutaneous coronary intervention (PCI) related MI is termed type 4a MI. * Coronary artery bypass grafting (CABG) related MI is termed type 5 MI. Revascularization is clinically driven if the target lesion diameter stenosis is \> 50% by quantitative coronary angiography (QCA) and the subject has clinical or functional ischemia which cannot be explained by another native coronary or bypass graft lesion.

    Time frame: 1 year FU

  4. Bleeding

    Bleeding BARC 2 or greater

    Time frame: 2 year

Other outcomes

  1. Composite of cardiovascular death, target vessel MI and ischemia-driven TLR (TLF)

    Cardiovascular death is defined as death resulting from cardiovascular causes. Any MI not clearly attributable to a non-target vessel will be considered as target-vessel MI. Revascularization is clinically driven if the target lesion diameter stenosis is \> 50% by quantitative coronary angiography (QCA) and the subject has clinical or functional ischemia which cannot be explained by another native coronary or bypass graft lesion.

    Time frame: 2 year FU

  2. Occurrence of cardiovascular death and target-vessel myocardial infarction (MI)

    Cardiovascular death is defined as death resulting from cardiovascular causes. The following categories may be collected: 1. Death caused by acute MI 2. Death caused by sudden cardiac, including unwitnessed, death 3. Death resulting from heart failure 4. Death caused by stroke 5. Death caused by cardiovascular procedures 6. Death resulting from cardiovascular hemorrhage 7. Death resulting from other cardiovascular cause. Any MI not clearly attributable to a non-target vessel will be considered as target-vessel MI. * Percutaneous coronary intervention (PCI) related MI is termed type 4a MI. * Coronary artery bypass grafting (CABG) related MI is termed type 5 MI.

    Time frame: 2 year

  3. All-cause mortality

    all deaths are considered cardiovascular unless an alternate cause is unequivocally established, even among subjects with serious noncardiac comorbidities.

    Time frame: up to 2 years from procedure

  4. Stroke

    according to Neuro-ARC stroke/TIA criteria

    Time frame: up to 2 years from procedure

  5. Stent thrombosis

    defined for grade and timing according to the Academic Research Consortium2

    Time frame: 2 year

  6. Technical success

    Technical success is defined as the ability to cross the occluded segment with both a wire and a balloon, and successfully open the artery; the restoration of antegrade TIMI flow 2 or 3 and a \<30% residual stenosis. (As applies to chronic total occlusion - CTO - lesions)

    Time frame: 2 year

  7. Clinical procedural success

    In the case of percutaneous intervention for obstructive lesions, procedural success is defined as the achievement of a final residual diameter stenosis \< 30% by angiography at the end of the procedure (and without flow limiting arterial dissection and hemodynamically significant translesional pressure gradient) without any in-hospital major adverse events (death, acute onset of limb ischemia, need for urgent/emergent vascular surgery). The balloon inflation and/or stent placement may be preceded by use of adjunctive devices (e.g., percutaneous mechanical thrombectomy, directional or rotational atherectomy, laser, chronic total occlusion crossing device). Ideally, the assessment of the residual stenosis at the end of the procedure should be performed by an angiographic core laboratory.

    Time frame: 2 year

  8. Occurrence of ischemia-driven TLR

    Revascularization is clinically driven if the target lesion diameter stenosis is \> 50% by quantitative coronary angiography (QCA) and the subject has clinical or functional ischemia which cannot be explained by another native coronary or bypass graft lesion.

    Time frame: 2 year FU

  9. Target vessel revascularization (TVR)

    TLR is a repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion.

    Time frame: up to 2 years

07

Study locations

90 sites
  • The Prince Charles Hospital
    Chermside, Australia
  • St Vincent Hospital
    Melbourne, Australia
  • The Wollongong Hospital
    Wollongong, Australia
  • University Heart Center Graz
    Graz, Austria
  • Kardinal Schwarzenberg Klinikum
    Schwarzach im Pongau, Austria
  • National Heart Foundation Hospital & Research Institute
    Dhaka, Bangladesh
  • Antwerp Cardiovascular Center Middelheim
    Antwerp, Belgium
  • UZ Leuven
    Leuven, Belgium
  • Instituto Dante Pazzanese de Cardiologia
    São Paulo, Brazil
  • INSTITUTO DO CORAÇÃO - InCor University of São Paulo Medical School
    São Paulo, Brazil
  • University Hospital Brno, Department of Medecine Cardiology
    Brno, Czechia
  • University Hospital Královské Vinohrady, Department of Medecine Cardiology
    Prague, Czechia
  • Clinique Axium
    Aix-en-Provence, France
  • CHRU Brest
    Brest, France
  • Clinique de Fontaine
    Fontaine-lès-Dijon, France
  • Groupe Hospitalier Mutualiste de Grenoble
    Grenoble, France
  • Hôpital La Timone, Service Cardiologie
    Marseille, France
  • Hôpital Privé Jacques Cartier
    Massy, France
  • CHU de Nîmes
    Nîmes, France
  • Hôpital Cochin
    Paris, France
  • Klinik für Kardiologie und Angiologie II, Herz-Zentrum Bad Krozingen
    Bad Krozingen, Germany
  • Kerckhoff-Klinik GmbH Abteilung Kardiologie/Herzchirurgie
    Bad Nauheim, Germany
  • Herzzentrum, Segeberger Kliniken GmbH
    Bad Segeberg, Germany
  • Charite Berlin, Department of Cardiology, Campus Benjamin Franklin
    Berlin, Germany
  • Helios Amper-Klinikum Dachau, Dept. of Cardiology & Pneumology
    Dachau, Germany
  • Elisabeth Krankenhaus Essen
    Essen, Germany
  • 121/ MVZ Hamburg, DEU
    Hamburg, Germany
  • UKSH, Campus Kiel, Department of Cardiology
    Kiel, Germany
  • Heart Center Leipzig
    Leipzig, Germany
  • Universitaetsklinikum Tubingen, DEU
    Tübingen, Germany
  • Schwarzwald Baar Klinikum Villingen-Schwenningen GmbH
    Villingen-Schwenningen, Germany
  • Madras Medical Mission
    Chennai, India
  • Krishna Institute of Medical Sciences
    Secunderabad, India
  • National University of Ireland, Galway Galway University Hospital
    Galway, Ireland
  • IRCCS - Policlinico San Donato
    San Donato Milanese, Milano, Italy
  • GVM - Cotignola
    Cotignola, Ravenna, Italy
  • Fondazione Poliambulanza di Brescia
    Brescia, Italy
  • P.O. G. Rodolico
    Catania, Italy
  • 075/ Magna Graecia University
    Catanzaro, Italy
  • Casa di Cura Montevergine
    Mercogliano, Italy
  • Istituto Sant'Ambrogio
    Milan, Italy
  • San Carlo Clinic
    Milan, Italy
  • San Raffaele Hospital
    Milan, Italy
  • 133/Clinica Mederranea
    Naples, Italy
  • Division of Cardiology, University of Campania "Luigi Vanvitelli"
    Naples, Italy
  • 156/ Policlinico San Matteo
    Pavia, Italy
  • Ospedale degli infermi
    Rivoli, Italy
  • Azienda Ospedaliera San Camillo Forlanini
    Roma, Italy
  • Policlinico Umberto I, "Sapienza" University of Rome Dept.of Cardiovascular, Respiratory, Nephrologic & Anesthesiologic Sciences
    Roma, Italy
  • Institut Jantung Negara
    Kuala Lumpur, Malaysia
  • Instituto nacional de cardiologia ignacio chavez
    Mexico City, Mexico
  • Grupo Intervención San Luis - Hospital de Especialidades de la Salud - San Luis Potosí City
    San Luis Potosí City, Mexico
  • IMSS Hospital de Especialidades UMAE 71
    Torreón, Mexico
  • Amsterdam UMC
    Amsterdam, Netherlands
  • Maasstad Hospital
    Rotterdam, Netherlands
  • XII Oddział Kardiologiczny PAKS w Bełchatowie
    Bełchatów, Poland
  • Polsko-Amerykańskie Kliniki Serca III Oddział Kardiologii Inwazyjnej, Angiologii i Elektrokardiologii
    Bielsko-Biala, Poland
  • MCSN AHoP Chrzanow
    Chrzanów, Poland
  • Zgierskie Centrum Kardiologii Med-Pro Polsko-Amerykańskie Kliniki Serca
    Dąbrowa Górnicza, Poland
  • American Heart of Poland
    Kędzierzyn-Koźle, Poland
  • University Hospital Krakow
    Krakow, Poland
  • Miedziowe Centrum Zdrowia SA
    Lubin, Poland
  • Nyskie Centrum Kardiologiczne Polsko-Amerykańskich Klinik Serca w Nysie
    Nysa, Poland
  • Centrum Kardiologii Inwazyjnej, Elektroterapii i Angiologii w Pińczowie
    Pińczów, Poland
  • Szpital Kliniczny Przemienienia Pańskiego
    Poznan, Poland
  • Oddział Kardiologii Szpitale Polskie Sztum
    Sztum, Poland
  • X Department of Invasive Cardiology, Tychy American Heart of Poland SA
    Tychy, Poland
  • I Oddział Kardiologii AHoP
    Ustroń, Poland
  • Department of Interventional Cardiology Med-Pro American Heart of Poland
    Zgierz, Poland
  • Changi General Hospital
    Singapore, Singapore
  • Gachon University Gil Medical Center
    Incheon, South Korea
  • Örebro Univ. Hospital, Dpt. of cardiology
    Örebro, Sweden
  • Uppsala University hosp
    Uppsala, Sweden
  • Cardiocentro Ticino
    Lugano, Switzerland
  • Hôpital de La Tour
    Meyrin, Switzerland
  • Triemli Hospital
    Zurich, Switzerland
  • University Hospital Zürich
    Zurich, Switzerland
  • National Cheng Kung University Hospital
    Tainan, Taiwan
  • Mackay Memorial Hospital
    Taipei, Taiwan
  • Belfast Health and Social Care Trust
    Belfast, United Kingdom
  • Royal blackburn hospital
    Blackburn, United Kingdom
  • The Royal Bournemouth Hospital
    Bournemouth, United Kingdom
  • Brighton & Sussex University NHS Hospitals Trust
    Brighton, United Kingdom
  • Golden Jubilee National Hospital
    Clydebank, United Kingdom
  • Craigavon Area Hospital
    Craigavon, United Kingdom
  • Ninewells Hospital
    Dundee, United Kingdom
  • King's College Hospital NHS Foundation Trust
    London, United Kingdom
  • Royal Free Hopsital
    London, United Kingdom
  • Freeman Hospital
    Newcastle upon Tyne, United Kingdom
  • Worcestershire Acute NHS Trust, Worcestershire Royal Hospital
    Worcester, United Kingdom
08

References and documents

Publications

  • International Diabetes Federation 2015. IDF DIABETES ATLAS Seventh Edition. 2015; ISBN: 978-2-930229-81-2
  • Thiele H, Zeymer U. Chapter: Cardiogenic shock in patients with acute coronary syndromes (p. 441), The ESC Textbook of Intensive and Acute Cardiovascular Care (2 ed.) [IACC]. Edited by Marco Tubaro, Pascal Vranckx, Susanna Price, and Christiaan Vrints. Updated on 22 February 2018 DOI: 10.1093/med/9780199687039.003.0049_update_003
  • Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol. 2010 Dec 14;56(25):2084-9. doi: 10.1016/j.jacc.2010.10.006. PubMed 21144968 ↗
  • Kufner S, Byrne RA, Dommasch M, Massberg S, Schoemig A, Kastrati A. Comparison of "limus"-eluting stents with permanent-vs biodegradable polymer in patients with diabetes mellitus with coronary artery disease. Eur Heart J 2012; 33: 558-9
  • Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation. 2011 Aug 23;124(8):893-900. doi: 10.1161/CIRCULATIONAHA.111.031070. Epub 2011 Aug 8. PubMed 21824922 ↗
  • Cutlip DE, Chhabra AG, Baim DS, Chauhan MS, Marulkar S, Massaro J, Bakhai A, Cohen DJ, Kuntz RE, Ho KK. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation. 2004 Sep 7;110(10):1226-30. doi: 10.1161/01.CIR.0000140721.27004.4B. Epub 2004 Aug 30. PubMed 15337693 ↗
  • Lee TT, Feinberg L, Baim DS, Holmes DR, Aroesty JM, Carrozza JP Jr, Cohen DJ, Ho KK, Cutlip DE. Effect of diabetes mellitus on five-year clinical outcomes after single-vessel coronary stenting (a pooled analysis of coronary stent clinical trials). Am J Cardiol. 2006 Sep 15;98(6):718-21. doi: 10.1016/j.amjcard.2006.03.059. Epub 2006 Jul 13. PubMed 16950169 ↗
  • Morgan KP, Kapur A, Beatt KJ. Anatomy of coronary disease in diabetic patients: an explanation for poorer outcomes after percutaneous coronary intervention and potential target for intervention. Heart. 2004 Jul;90(7):732-8. doi: 10.1136/hrt.2003.021014. PubMed 15201238 ↗
  • Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3(6):853-76. PubMed 18200806 ↗
  • Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond). 2005 Aug;109(2):143-59. doi: 10.1042/CS20050025. PubMed 16033329 ↗
  • Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010 Nov 30;56(23):1897-907. doi: 10.1016/j.jacc.2010.07.028. PubMed 21109112 ↗
  • Lightell DJ Jr, Woods TC. Relative resistance to Mammalian target of rapamycin inhibition in vascular smooth muscle cells of diabetic donors. Ochsner J. 2013 Spring;13(1):56-60. PubMed 23532775 ↗
  • Denardo SJ, Carpinone PL, Vock DM, Batich CD, Pepine CJ. Changes to polymer surface of drug-eluting stents during balloon expansion. JAMA. 2012 May 23;307(20):2148-50. doi: 10.1001/jama.2012.4111. No abstract available. PubMed 22618916 ↗
  • Popma JJ, Leon MB, Moses JW, Holmes DR Jr, Cox N, Fitzpatrick M, Douglas J, Lambert C, Mooney M, Yakubov S, Kuntz RE; SIRIUS Investigators. Quantitative assessment of angiographic restenosis after sirolimus-eluting stent implantation in native coronary arteries. Circulation. 2004 Dec 21;110(25):3773-80. doi: 10.1161/01.CIR.0000150331.14687.4B. Epub 2004 Dec 13. PubMed 15596568 ↗
  • Mulukutla SR, Vlachos HA, Marroquin OC, Selzer F, Holper EM, Abbott JD, Laskey WK, Williams DO, Smith C, Anderson WD, Lee JS, Srinivas V, Kelsey SF, Kip KE. Impact of drug-eluting stents among insulin-treated diabetic patients: a report from the National Heart, Lung, and Blood Institute Dynamic Registry. JACC Cardiovasc Interv. 2008 Apr;1(2):139-47. doi: 10.1016/j.jcin.2008.02.005. PubMed 19212456 ↗
  • Stenestrand U, James SK, Lindback J, Frobert O, Carlsson J, Schersten F, Nilsson T, Lagerqvist B; SCAAR/SWEDEHEART study group. Safety and efficacy of drug-eluting vs. bare metal stents in patients with diabetes mellitus: long-term follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J. 2010 Jan;31(2):177-86. doi: 10.1093/eurheartj/ehp424. Epub 2009 Nov 10. PubMed 19903684 ↗
  • Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: the diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am J Cardiol. 2009 Feb 1;103(3):345-9. doi: 10.1016/j.amjcard.2008.09.084. Epub 2008 Nov 12. PubMed 19166687 ↗
  • Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A; ISAR-DIABETES Study Investigators. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med. 2005 Aug 18;353(7):663-70. doi: 10.1056/NEJMoa044372. Epub 2005 Aug 16. PubMed 16105990 ↗
  • Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008 Apr 23;299(16):1903-13. doi: 10.1001/jama.299.16.1903. PubMed 18430909 ↗
  • Mahmud E, Ormiston JA, Turco MA, Popma JJ, Weissman NJ, O'Shaughnessy CD, Mann T, Hall JJ, McGarry TF, Cannon LA, Webster MW, Mandinov L, Baim DS. TAXUS Liberte attenuates the risk of restenosis in patients with medically treated diabetes mellitus: results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2009 Mar;2(3):240-52. doi: 10.1016/j.jcin.2008.12.009. PubMed 19463432 ↗
  • Serruys PW, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrie D, Thuesen L, Boone E, Miquel-Herbert K, Daemen J. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. EuroIntervention. 2006 Nov;2(3):286-94. PubMed 19755303 ↗
  • Grube E, Chevalier B, Guagliumi G, Smits PC, Stuteville M, Dorange C, Papeleu P, Kaul U, Dzavik V. The SPIRIT V diabetic study: a randomized clinical evaluation of the XIENCE V everolimus-eluting stent vs the TAXUS Liberte paclitaxel-eluting stent in diabetic patients with de novo coronary artery lesions. Am Heart J. 2012 May;163(5):867-875.e1. doi: 10.1016/j.ahj.2012.02.006. Epub 2012 Apr 11. PubMed 22607866 ↗
  • Garcia-Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, Onuma Y, Morel MA, van Es GA, Zuckerman B, Fearon WF, Taggart D, Kappetein AP, Krucoff MW, Vranckx P, Windecker S, Cutlip D, Serruys PW; Academic Research Consortium. Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. Eur Heart J. 2018 Jun 14;39(23):2192-2207. doi: 10.1093/eurheartj/ehy223. PubMed 29897428 ↗
  • Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, White HD; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018 Oct 30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038. Epub 2018 Aug 25. No abstract available. PubMed 30153967 ↗
  • Lansky AJ, Messe SR, Brickman AM, Dwyer M, van der Worp HB, Lazar RM, Pietras CG, Abrams KJ, McFadden E, Petersen NH, Browndyke J, Prendergast B, Ng VG, Cutlip DE, Kapadia S, Krucoff MW, Linke A, Moy CS, Schofer J, van Es GA, Virmani R, Popma J, Parides MK, Kodali S, Bilello M, Zivadinov R, Akar J, Furie KL, Gress D, Voros S, Moses J, Greer D, Forrest JK, Holmes D, Kappetein AP, Mack M, Baumbach A. Proposed Standardized Neurological Endpoints for Cardiovascular Clinical Trials: An Academic Research Consortium Initiative. J Am Coll Cardiol. 2017 Feb 14;69(6):679-691. doi: 10.1016/j.jacc.2016.11.045. PubMed 28183511 ↗
  • Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449. No abstract available. PubMed 21670242 ↗
  • Abizaid A, Mehran R, Oliva A, Chamie D, Staico R, Malik F, Vink M, Kurniadi A, Cao D, Capranzano P, Faurie B, Garot P, Hildick-Smith D, Ielasi A, Loffelhardt N, Kedev S, Mylotte D, Milewski K, Paradies V, Schmitz T, Teeuwen K, Testa L, Toelg R, Vochelet F, Vogel B, Wykrzykowska J, Sartori S, Colombo A, Saito S, Morice MC; ABILITY Diabetes Global investigators. Abluminus DES+ sirolimus-eluting stent versus everolimus-eluting stent in patients with diabetes and coronary artery disease (ABILITY Diabetes Global): results from a multicentre, randomised controlled trial. Lancet. 2026 Jan 17;407(10525):227-236. doi: 10.1016/S0140-6736(25)02157-9. Epub 2026 Jan 8. PubMed 41520674 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Nov 2023, 41 months.

Of 160 industry-sponsored interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 41 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Oct 2023 → Nov 2023 and completion Sep 2024 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Jan 22, 2020
StartActual
Jun 15, 2020
Primary completionActual
Nov 30, 2023was Oct 2023
CompletionActual
Nov 30, 2024was Sep 2024
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Oct 26, 2026
Sites
17 sites added, 17 sites removed
Show 17 added (5 Italy, 2 Mexico, 2 Switzerland, 2 Taiwan, 1 Austria, 1 Belgium, 1 Czechia, 1 Germany, 1 Poland, 1 United Kingdom)
  • Kardinal Schwarzenberg Klinikum · Schwarzach im Pongau, Austria
  • Antwerp Cardiovascular Center Middelheim · Antwerp, Belgium
  • University Hospital Královské Vinohrady, Department of Medecine Cardiology · Prague, Czechia
  • Universitaetsklinikum Tubingen, DEU · Tübingen, Germany
  • Istituto Sant'Ambrogio · Milan, Italy
  • San Carlo Clinic · Milan, Italy
  • San Raffaele Hospital · Milan, Italy
  • 133/Clinica Mederranea · Naples, Italy
  • Division of Cardiology, University of Campania "Luigi Vanvitelli" · Naples, Italy
  • Grupo Intervención San Luis - Hospital de Especialidades de la Salud - San Luis Potosí City · San Luis Potosí City, Mexico
  • IMSS Hospital de Especialidades UMAE 71 · Torreón, Mexico
  • Szpital Kliniczny Przemienienia Pańskiego · Poznan, Poland
  • Triemli Hospital · Zurich, Switzerland
  • University Hospital Zürich · Zurich, Switzerland
  • National Cheng Kung University Hospital · Tainan, Taiwan
  • Mackay Memorial Hospital · Taipei, Taiwan
  • Freeman Hospital · Newcastle upon Tyne, United Kingdom
Show 17 removed
  • Kardinal Schwarzenberg Klinikum · Schwarzach Im Pongau, Austria
  • Antwerp Cardiovascular Center Middelheim · Antwerpen, Belgium
  • University Hospital Královské Vinohrady, Department of Medecine Cardiology · Praha, Czechia
  • Universitaetsklinikum Tubingen, DEU · Tuebingen, Germany
  • Istituto Sant'Ambrogio · Milano, Italy
  • San Carlo Clinic · Milano, Italy
  • San Raffaele Hospital · Milano, Italy
  • 133/Clinica Mederranea · Napoli, Italy
  • Division of Cardiology, University of Campania "Luigi Vanvitelli" · Napoli, Italy
  • Grupo Intervención San Luis - Hospital de Especialidades de la Salud - San Luis Potosí City · San Luis Potosí, Mexico
  • IMSS Hospital de Especialidades UMAE 71 · Torreon, Mexico
  • Szpital Kliniczny Przemienienia Pańskiego · Poznań, Poland
  • Triemli Hospital · Zürich, Switzerland
  • University Hospital Zürich · Zürich, Switzerland
  • National Cheng Kung University Hospital · Tainan City, Taiwan
  • Mackay Memorial Hospital · Taipei City, Taiwan
  • Freeman Hospital · Newcastle Upon Tyne, United Kingdom
Oct 26, 2026
Primary completion
Oct 30, 2023→Nov 30, 2023 (actual)
Oct 26, 2026
Study completion
Sep 30, 2024→Nov 30, 2024 (actual)
Oct 26, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41520674 ↗
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Status unknown→Completed
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41520674 ↗
    17 sites added, 17 sites removed
    Show 17 added (5 Italy, 2 Mexico, 2 Switzerland, 2 Taiwan, 1 Austria, 1 Belgium, 1 Czechia, 1 Germany, 1 Poland, 1 United Kingdom)
    • Kardinal Schwarzenberg Klinikum · Schwarzach im Pongau, Austria
    • Antwerp Cardiovascular Center Middelheim · Antwerp, Belgium
    • University Hospital Královské Vinohrady, Department of Medecine Cardiology · Prague, Czechia
    • Universitaetsklinikum Tubingen, DEU · Tübingen, Germany
    • Istituto Sant'Ambrogio · Milan, Italy
    • San Carlo Clinic · Milan, Italy
    • San Raffaele Hospital · Milan, Italy
    • 133/Clinica Mederranea · Naples, Italy
    • Division of Cardiology, University of Campania "Luigi Vanvitelli" · Naples, Italy
    • Grupo Intervención San Luis - Hospital de Especialidades de la Salud - San Luis Potosí City · San Luis Potosí City, Mexico
    • IMSS Hospital de Especialidades UMAE 71 · Torreón, Mexico
    • Szpital Kliniczny Przemienienia Pańskiego · Poznan, Poland
    • Triemli Hospital · Zurich, Switzerland
    • University Hospital Zürich · Zurich, Switzerland
    • National Cheng Kung University Hospital · Tainan, Taiwan
    • Mackay Memorial Hospital · Taipei, Taiwan
    • Freeman Hospital · Newcastle upon Tyne, United Kingdom
    Show 17 removed
    • Kardinal Schwarzenberg Klinikum · Schwarzach Im Pongau, Austria
    • Antwerp Cardiovascular Center Middelheim · Antwerpen, Belgium
    • University Hospital Královské Vinohrady, Department of Medecine Cardiology · Praha, Czechia
    • Universitaetsklinikum Tubingen, DEU · Tuebingen, Germany
    • Istituto Sant'Ambrogio · Milano, Italy
    • San Carlo Clinic · Milano, Italy
    • San Raffaele Hospital · Milano, Italy
    • 133/Clinica Mederranea · Napoli, Italy
    • Division of Cardiology, University of Campania "Luigi Vanvitelli" · Napoli, Italy
    • Grupo Intervención San Luis - Hospital de Especialidades de la Salud - San Luis Potosí City · San Luis Potosí, Mexico
    • IMSS Hospital de Especialidades UMAE 71 · Torreon, Mexico
    • Szpital Kliniczny Przemienienia Pańskiego · Poznań, Poland
    • Triemli Hospital · Zürich, Switzerland
    • University Hospital Zürich · Zürich, Switzerland
    • National Cheng Kung University Hospital · Tainan City, Taiwan
    • Mackay Memorial Hospital · Taipei City, Taiwan
    • Freeman Hospital · Newcastle Upon Tyne, United Kingdom
    Primary completion Oct 30, 2023→Nov 30, 2023 (now actual)
    Study completion Sep 30, 2024→Nov 30, 2024 (now actual)
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04236609
Lead sponsor
Concept Medical Inc.
Responsible party
Sponsor
First posted
Jan 22, 2020
Start date
Jun 15, 2020
Primary completion
Nov 30, 2023
Completion
Nov 30, 2024
Last update
Oct 26, 2026

Study contacts

Roxana Mehran
study chair · Mount Sinai Heart

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion